secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2024-09-09T23:59:59+00:00
Accession:  0001104659-24-098149
Event type: regulatory
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel submits Phase 3 protocol for BXCL501 in Alzheimer's agitation to FDA
----------------------------------------------------------------------------

- Submitted TRANQUILITY In-Care Phase 3 protocol for 60 mcg BXCL501 to FDA on Sept 5, 2024.
- Trial targets agitation associated with Alzheimer's dementia.
- No additional details on trial design or timeline were disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465924098149/0001104659-24-098149-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465924098149/tm2423619d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-098149

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer